Influenza Treatment Market Size, Growth Analysis, Growth Demands, Forecast to 2033

Influenza treatment refers to medical interventions aimed at managing and alleviating symptoms, reducing the duration of illness, and preventing complications associated with influenza virus infections. Influenza treatments encompass antiviral medications and supportive care designed to mitigate flu symptoms, reduce disease duration, and prevent severe complications.

Sizing and Forecast

The influenza treatment market size has grown steadily in recent years. It will grow from $6.34 billion in 2023 to $6.60 billion in 2024 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to a growth in number of annual influenza cases, increased government funding for influenza research and preparedness programs, public awareness campaigns promoting vaccination, the establishment of global influenza surveillance systems, and growth in healthcare facilities.

The influenza treatment market size is expected to see steady growth in the next few years. It will grow to $7.83 billion in 2028 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to the introduction of new antiviral drugs and treatment modalities, expanding vaccination programs, continued expansion and improvement of healthcare infrastructure, increasing elderly population, and development of new treatments. Major trends in the forecast period include progress toward developing universal vaccines, innovations in vaccine delivery systems, integration of AI and big data, advances in personalized medicine, and increased collaborations between pharmaceutical companies.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report

Segmentation & Regional Insights

The influenza treatment market covered in this report is segmented –

1) By Product Type: Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, Other Products
2) By Route Of Administration: Oral, Other Routes Of Administration
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels

North America was the largest region in the influenza treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15832&type=smp

Major Driver Impacting Market Growth

The increased prevalence of contagious respiratory illnesses is expected to propel the influenza treatment market going forward. Contagious respiratory illness refers to an infectious disease, such as influenza, measles, or respiratory syncytial virus (RSV) infections, transmitted through contact with an infected individual or their bodily fluids, contaminated surfaces, or objects. Factors driving the growth of contagious respiratory illness include higher population densities, inadequate healthcare infrastructure, misuse of antibiotics, and international travel facilitation. Influenza treatment consists of antiviral drugs and vaccinations that are used to treat various contagious respiratory illnesses such as flu, COVID-19, and other respiratory viruses. For instance, in September 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, the rate of hospitalizations linked to RSV (Respiratory Syncytial Virus) surged from 2 hospitalizations per 100,000 people during the week ending August 5, 2023, to 7 hospitalizations per 100,000 individuals by the week concluding on August 19, 2023. Therefore, the increased prevalence of contagious respiratory illnesses is driving the growth of the influenza treatment market.

Key Industry Players

Major companies operating in the influenza treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline Plc , Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Fujifilm Holdings Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited., Chugai Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Cipla Ltd, Dr. Reddy’s Laboratories Ltd., Lupin Limited, NATCO Pharma Limited, BioCryst Pharmaceuticals Inc., NanoViricides Inc.

The influenza treatment market report table of contents includes:

1. Executive Summary
2. Influenza Treatment Market Characteristics
3. Influenza Treatment Market Trends And Strategies
4. Influenza Treatment Market – Macro Economic Scenario
5. Global Influenza Treatment Market Size and Growth
.
.
.
32. Global Influenza Treatment Market Competitive Benchmarking
33. Global Influenza Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Influenza Treatment Market
35. Influenza Treatment Market Future Outlook and Potential Analysis
36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model